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Abstract
Background: The SARS- CoV-2 virus causing COVID-19 binds human angiotensin- converting enzyme 2 
(ACE2) receptors in human tissues. ACE2 expression may be associated with COVID-19 infection and 
mortality rates. Routinely prescribed drugs that up- or down- regulate ACE2 expression are, therefore, 
of critical research interest as agents that might promote or reduce risk of COVID-19 infection in a 
susceptible population.
Aim: To collate evidence on routinely prescribed drug treatments in the UK that could up- or down- 
regulate ACE2, and thus potentially affect COVID-19 infection.
Design & setting: Systematic review of studies published in MEDLINE, Embase, CINAHL (Cumulative 
Index to Nursing and Allied Health Literature), the Cochrane Library, and Web of Science from 
inception to 1 April 2020.
Method: A systematic review will be conducted in line with the Preferred Reporting Items for 
Systematic Review and Meta- Analysis (PRISMA) guidelines. Inclusion criteria will be: (1) assesses the 
effect of drug exposure on ACE2 level of expression or activity; (2) the drug is included in the British 
National Formulary (BNF) and, therefore, available to prescribe in the UK; and (3) a control, placebo, 
or sham group is included as comparator. Exclusion criteria will be: (1) ACE2 measurement in utero; (2) 
ACE2 measurement in children aged <18 years; (3) drug not in the BNF; and (4) review article. Quality 
will be assessed using the Cochrane risk of bias tool for human studies, and the SYstematic Review 
Center for Laboratory animal Experimentation (SYRCLE) risk of bias tool for animal studies.
Results: Data will be reported in summary tables and narrative synthesis.
Conclusion: This systematic review will identify drug therapies that may increase or decrease ACE2 
expression. This might identify medications increasing risk of COVID-19 transmission, or as targets for 
intervention in mitigating transmission.
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How this fits in
Clinicians, researchers, and patients are increasingly interested in whether existing drug treatments 
may influence outcomes in COVID-19. As the binding site for SARS- CoV-2, ACE2 is of particular 
interest. This systematic review will identify what evidence exists on the effects of drugs prescribed 
in the UK on ACE2 levels of gene expression or activity. The findings will highlight drugs that might 
promote or prevent transmission of COVID-19.
Introduction
The rapid spread of the novel, pathogenic severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2) between late 2019 and April 2020 has escalated to a global health emergency.1 As of 10 July 
2020, almost 12 million individuals have been infected worldwide, and there have been over 500 
000 deaths associated with COVID-19 (coronavirus disease 2019).2 Focus on strategies to reduce 
viral transmission and disease mortality has intensified, including both pharmacological3 and non- 
pharmacological approaches,4,5 alongside high- speed vaccine development programmes.6
SARS- CoV-2 has been shown to enter cells via binding to the angiotensin- converting enzyme 2 
(ACE2).7 The ACE2 receptor performs a broad range of roles in a variety of tissues, including lung, 
kidney, brain, and heart.8 As part of the renin- angiotensin- aldosterone system (RAAS), ACE2 is 
implicated in roles including blood pressure homeostasis9 and downregulation of inflammation.10 It 
has been hypothesised that SARS- CoV-2 may mediate effects contributing to viral sepsis and mortality 
through interaction with ACE2 in a variety of tissues.11,12 Furthermore, differential expression of ACE2 
in disease states, such as hypertension, may be associated with differing rates of COVID-19 infection 
or mortality.13
A key research question is whether any routinely prescribed drugs may be associated with altered 
ACE2 expression, and whether this altered expression may be of clinical relevance in COVID-19. 
For example, debate is ongoing about whether patients taking ACE inhibitors should be advised 
to switch drug class owing to their association with increased ACE2 expression.14–16 Conversely, 
medications that downregulate ACE2 expression may be of interest as part of a strategy to reduce 
viral transmission.17 While recent studies have discussed the evidence surrounding ACE inhibitors and 
angiotensin receptor blockers in the context of COVID-19,18 the evidence for the effects of a broader 
range of drugs remains unclear.
This systematic review seeks to identify what evidence exists on drug therapies that may influence 
levels of ACE2 gene expression or enzymatic activity. Identifying drugs with these effects will help 
direct future COVID-19 research by highlighting drugs that may either prevent or promote transmission 
of the disease and, therefore, be appropriate candidates for further research. To maximise the ability 
of this review to identify drugs that could be candidates for further investigation, both human and 
animal studies will be included.
Method
Protocol development
The systematic review will be conducted in line with guidance set out in the PRISMA and PRISMA- 
Protocol statements.19,20
Table 1 Search strategies to be used in systematic review, described by database to be searched
Terms Database
(ace2[Title/Abstract]) OR ace 2[Title/Abstract] Filters: English MEDLINE (PubMed)
(ace2 or ace 2).ab. and English.lg Embase
ace2 in Title Abstract Keyword OR ace-2 in Title Abstract Keyword (Word 
variations have been searched)
Cochrane
(TS=(ace2 OR ace-2)) AND LANGUAGE: (English) AND DOCUMENT TYPES: 
(Article)
Web of Science
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Search strategy
Systematic searches will be conducted from database inception until 1 April 2020 in the following 
databases: MEDLINE, Embase, CINAHL, the Cochrane Library, and Web of Science. The detailed 
search strategy is provided in Table 1. References of relevant reviews and articles meeting selection 
criteria will additionally be screened; advice will be sought from topic experts; and OpenGrey will be 
searched to identify additional texts. No study design filters will be set on the search. Articles will be 
limited to English language.
Study selection criteria
The study inclusion criteria will be:
1. studies measuring ACE2 levels (of either activity or gene expression);
2. studies including a drug that is available on a UK prescription according to the BNF;21
3. studies measuring the effect of the drug on levels of ACE2 expression or activity against a 
control, placebo, or sham group.
Study exclusion criteria will be:
1. ACE2 measurements in utero;
2. studies in children aged <18 years;
3. the medication being studied is not available to prescribe in primary care in the UK, as assessed 
by inclusion in the BNF;
4. review articles.
All methodologies will be eligible for inclusion, including randomised and non- randomised trials 
alongside other experimental approaches. Conference abstracts will be included if sufficient data can 
be elicited from them. Review articles will be excluded from synthesis, but their references will be 
screened and all appropriate studies included.
Screening and data extraction
Study titles and abstracts will be reviewed for eligibility by four members of the review team (AA, 
HDM, CW, SH). Full- text review, data extraction, and quality assessment will be performed by five 
members of the team (AA, HDM, CW, SH, SK). Initial screening will be performed using the systematic 
review web app Rayyan QCRI.22 In order to rapidly appraise the evidence, each abstract or full text will 
be assessed by one reviewer. For any piece of evidence on which the reviewer is uncertain, at least two 
reviewers will perform abstract and full- text screening. Disagreement will be resolved by discussion 
between all reviewers.
The following data will be extracted and verified by one of the five members of the review team (AA, 
HDM, CW, SH, SK): (1) drug class; (2) drug name; (3) duration of treatment; (4) effect on ACE2 level 
(defined as upregulation, or downregulation, or no effect); (5) model (for example, human, mouse); 
(6) site of ACE2 receptor (for example, lung, brain); (7) study design; (8) study population (including 
disease state studied for human and animal model studies); (9) sample size; and (10) country. Given 
the urgency of this research question during the COVID-19 pandemic, all available information will be 
extracted from the text, but authors will not be separately contacted. Data extraction processes will 
be standardised between members of the review team through comparison and discussion. The data 
extraction tool will be piloted and adapted as required in the early phases of data extraction.
Quality assessment
Methodological quality of included animal studies will be assessed using the SYRCLE risk of bias 
tool.23 This tool has been adapted from the Cochrane risk of bias tool for randomised studies24 to 
include criteria to specifically assess the quality of animal studies. The quality of human studies will be 
analysed separately using the Cochrane risk of bias tool. Quality assessment will be performed at the 
time of data extraction by the reviewer extracting the data.
Summary tables and narrative synthesis
Numbers of studies identified in searches and subsequently included in analysis will be demonstrated 
using the PRISMA flowchart in line with PRISMA guidance.19 Extracted data will be presented in 
summary tables to meet the primary objective of this review.
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Given the expected heterogeneity in study designs, models included in analysis (including in vivo 
and in vitro human and animal studies), and methods for measuring ACE2, meta- analysis via forest 
plots will not be appropriate.
A narrative synthesis of results will be produced. This will delineate human from animal studies, and 
priority will be given to human studies, using sensitivity analyses where appropriate. Furthermore, the 
tissue in which the study has taken place (for example, lung, kidney) will be discussed; priority will be 
given to tissues more relevant to COVID-19 infection, in particular lung.
Where inconsistencies are identified in the effect of a drug between studies, additional data will 
be considered such as materials, quality of study, population studied, and outcome measurement for 
potential explanatory factors.
Patient and public involvement
Patients and the public were not directly involved in the design of this study owing to funding 
limitations. Patients have been invited to help the authors to develop the dissemination strategy.
Amendments
Any amendments to this protocol will be documented and communicated in the final prepared 
manuscript.
Dissemination
The results of this review will be published in an open access journal to ensure free and immediate 
access for researchers and clinicians. Findings will also be disseminated in various media, including 
through presentation at medical conferences and through digital platforms, including research group 
websites and social media.
Discussion
Summary
This review will deliver timely and key answers to an important question amidst the COVID-19 
pandemic: do any routinely prescribed drugs up- or down- regulate levels of ACE2 expression or 
activity, and therefore play a potential role in disease transmission?
Strengths and limitations
The strengths of this review protocol include its broad search strategy; inclusion of both human and 
animal studies;and the intention to rapidly assess and synthesise the evidence to meet the pressing 
research needs of the COVID-19 pandemic. Extracting data on study population will help researchers 
critique the relevance to local populations. Extracting data on the tissue in which ACE2 levels of 
expression or activity are being studied may help inform the relevance of these findings to COVID-19 
transmission; for example, by highlighting the effect on ACE2 in lung and vascular endothelium, both 
of which are believed to be highly relevant to COVID-19 pathophysiology.25,26
Weaknesses include anticipated heterogeneity across animal and human models, which may 
complicate result interpretation. Furthermore, it is not intended to contact authors of articles to 
obtain missing data owing to the need to urgently report findings amid the current pandemic. Finally, 
the fact that it is anticipated that very few articles will measure ACE2 levels of expression or activity in 
the context of COVID-19 will limit generalisability in the context of the current pandemic.
Comparison with existing literature
The authors believe that this will be the first systematic review assessing associations between drug 
exposure and levels of ACE2 expression or activity for drugs routinely prescribed in the UK.
Implications for practice
There is significant debate among clinicians around whether drugs associated with ACE2 expression 
should be stopped; for example, whether patients should be advised to stop ACE inhibitors.16 
Conversely, drugs that are associated with ACE2 downregulation might represent a therapeutic 
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strategy to reduce viral transmission and disease spread. This study will be an important first step in 
highlighting drugs warranting further research to inform patients and clinicians making these decisions.
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